Form 4: Lexeo Therapeutics Director Mette Kirstine Agger Granted 25,000 Stock Options

Lexeo Therapeutics, Inc. director Mette Kirstine Agger was granted 25,000 stock options with an exercise price of $4.18, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Summary

• Mette Kirstine Agger, a director of Lexeo Therapeutics, Inc. (LXEO), was granted 25,000 stock options.
• The options have an exercise price of $4.18 per share.
• The grant date for these options was June 26, 2025.
• The options will vest 100% on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, contingent on continuous service.
• The options expire on June 25, 2035.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (option grant) to a director, which is generally a neutral to slightly positive signal as it aligns interests, but it does not contain significant financial or operational news to warrant a strong sentiment.

Positives

• Granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options were granted at an exercise price of $4.18, which could be seen as a positive if the stock price appreciates above this level.

Future Outlook

The 25,000 stock options granted to Director Mette Kirstine Agger are scheduled to vest 100% on the earlier of June 26, 2026, or the date of Lexeo Therapeutics' next annual stockholders meeting, subject to her continuous service. The options have an expiration date of June 25, 2035.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of directors with those of shareholders by incentivizing long-term stock price appreciation.

Comparison to Industry Standards

• This document does not provide sufficient detail to compare the specific option grant to industry standards or specific comparable companies/projects. The size of the grant (25,000 options) and the exercise price ($4.18) would need to be evaluated against peer company compensation practices and Lexeo Therapeutics' market capitalization and stage of development.

Related Party Transactions

• Grant of 25,000 stock options to Mette Kirstine Agger, a director of Lexeo Therapeutics, Inc., with an exercise price of $4.18.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, as the options gain value only if the stock price increases above the exercise price. This could be seen as a positive for long-term shareholder value.

Next Steps

• The options are expected to vest on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting.

Key Dates

Recommendation

Keywords

Lexeo Therapeutics, LXEO, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Mette Kirstine Agger